Submitted by Anonymous (not verified) on 26 January 2026 - 14:00
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 16, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 16, Status: Authorised